Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this study is to compare the effects of tablet treatment, circadian and combined circadian and ultradian subcutaneous hydrocortisone infusion on steroid metabolism and tissue responses to therapy.
The conventional glucocorticoid replacement therapy in primary adrenal insufficiency (Addison's disease) and congenital adrenal hyperplasia renders the cortisol levels unphysiological, which may cause symptoms and long-term complications. This therapeutical approach does not enable to restore physiological circadian and ultradian rhythm of glucocorticoids. Current studies conclude that constant or unphysiological administration of glucocorticoids leads to abnormal gene transcription and causes sides effect of glucocorticoids treatment and long standing complications Glucocorticoid replacement is technically feasible by continuous subcutaneous hydrocortisone infusion, which can mimic not only the normal diurnal cortisol rhythm, but potentially also the ultradian cadence.
This is a pilot trial with an open cross-over design of 3 x minimum 2 weeks in 10 patients comparing the effects of tablet treatment versus continuous subcutaneous hydrocortisone infusion versus ultradian subcutaneous hydrocortisone infusion on serum, salivary, tissue hormonal response and glucocorticoid related gene expression.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| continuous subcutaneous hydrocortisone | Experimental | continuous subcutaneous hydrocortisone infusion (CSHI), Solu-Cortef ® 50mg/ml infusate |
|
| cortef tablets | Active Comparator | the patient regular treatment by Cortef 5 mg, produced by Nycomed Pharma two times or three times a day. |
|
| ultradian subcutaneous hydrocortisone | Experimental | ultradian subcutaneous hydrocortisone infusion, Solu-Cortef ® 50mg/ml infusate |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Solu-Cortef | Drug | administration by pump for minimum 2 weeks |
|
| Measure | Description | Time Frame |
|---|---|---|
| Serum cortisol -24 hours curve | admission to hospital for 24 hours | 24 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Salivary cortisol - 24 hours curve | admission to the hospital for 25 hours | 24 hours |
| 24 h urine cortisol and metabolites | urine samples for 24 hours |
Not provided
Inclusion Criteria:
Exclusion Criteria:.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Katerina Simunkova, MD, PhD | Universtity of Bergen | Principal Investigator |
| Kristian Løvås, MD, PhD | Helse Bergen | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital Helse Bergen | Bergen | 5021 | Norway |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 20842176 | Background | Lightman SL, Conway-Campbell BL. The crucial role of pulsatile activity of the HPA axis for continuous dynamic equilibration. Nat Rev Neurosci. 2010 Oct;11(10):710-8. doi: 10.1038/nrn2914. Epub 2010 Sep 15. | |
| 17609409 | Background | Lovas K, Husebye ES. Continuous subcutaneous hydrocortisone infusion in Addison's disease. Eur J Endocrinol. 2007 Jul;157(1):109-12. doi: 10.1530/EJE-07-0052. |
Not provided
Not provided
| Type | Date | Date Unknown |
|---|---|---|
| Release | Jun 12, 2024 | |
| Reset | Sep 27, 2024 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Jun 12, 2024 | Sep 27, 2024 |
| ID | Term |
|---|---|
| D000224 | Addison Disease |
| D000312 | Adrenal Hyperplasia, Congenital |
| ID | Term |
|---|---|
| D000309 | Adrenal Insufficiency |
| D000307 | Adrenal Gland Diseases |
| D004700 | Endocrine System Diseases |
| D001327 | Autoimmune Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C007133 | hydrocortisone hemisuccinate |
| D006854 | Hydrocortisone |
| ID | Term |
|---|---|
| D011282 | Pregnenediones |
| D011283 | Pregnenes |
| D011278 | Pregnanes |
| D013256 | Steroids |
| D000072473 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Cortef | Drug | tablet treatment 2 ro 3 times per day for 14 days |
|
|
| 24 hours |
| levels of corticotropic hormone | blood samples | 24 hours |
| 24 hours curve of tissue cortisol | The tissue effect of glucocorticoid replacement - 24 hours curve of tissue cortisol (microdialysis) | 24 hours |
| gene expression | m RNA expression of genes | 24 hours |
| 10752074 | Background | Lightman SL, Windle RJ, Julian MD, Harbuz MS, Shanks N, Wood SA, Kershaw YM, Ingram CD. Significance of pulsatility in the HPA axis. Novartis Found Symp. 2000;227:244-57; discussion 257-60. doi: 10.1002/0470870796.ch14. |
| 37172949 | Result | Simunkova K, Lovas K, Methlie P, Jovanovic N, Bifulco E, Bronstad I, Lightman SL, Husebye ES, Oksnes M. Pulsatile Subcutaneous Hydrocortisone Replacement in Primary Adrenal Insufficiency. Horm Metab Res. 2023 Jul;55(7):471-478. doi: 10.1055/a-2092-5228. Epub 2023 May 12. |
| D007154 | Immune System Diseases |
| D047808 | Adrenogenital Syndrome |
| D012734 | Disorders of Sex Development |
| D014564 | Urogenital Abnormalities |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D000013 | Congenital Abnormalities |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D030342 | Genetic Diseases, Inborn |
| D043202 | Steroid Metabolism, Inborn Errors |
| D008661 | Metabolism, Inborn Errors |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D006058 | Gonadal Disorders |
| Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
| D015062 | 11-Hydroxycorticosteroids |
| D006889 | Hydroxycorticosteroids |
| D000305 | Adrenal Cortex Hormones |
| D006728 | Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |
| D015065 | 17-Hydroxycorticosteroids |